Physician profile
Michael Smith
NPI 1538491311
$2,868.88
in general payments reported to CMS, 2019-2025
20 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $51.32 · 2021: $269 · 2022: $714 · 2023: $460 · 2024: $633 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $845.44 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Alcon Vision LLC | $298.35 | 2021-2024 | Clareon, Hydrus Microstent, Rocklatan |
| Nova Eye, INC. | $252.50 | 2025 | |
| Sight Sciences, INC. | $236.97 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Regeneron Healthcare Solutions, INC. | $217.60 | 2022-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $183.49 | 2020-2022 | |
| Glaukos Corporation | $175.29 | 2022-2025 | Idosetr, Istent Infinite |
| New World Medical,INC. | $167.73 | 2022 | |
| Rxsight INC | $119.00 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Tarsus Pharmaceuticals, INC. | $74.30 | 2025 | Xdemvy |
| Genentech USA, INC. | $66.46 | 2024-2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $47.87 | 2023-2024 | Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $44.30 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $34.63 | 2025 | Iluvien |
| Amgen INC. | $21.26 | 2025 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.26 | 2023 | |
| Thea Pharma INC. | $17.51 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $17.20 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.58 | 2024 | |
| Apellis Pharmaceuticals, INC. | $13.14 | 2024 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.